Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Repetitive levosimendan infusions for patients with advanced chronic heart failure (LeoDOR) A
randomised, double-blind, placebo-controlled multicentre study with parallel group design.
Mortality and rehospitalisation rates are high in the vulnerable phase following heart
failure hospitalisation. Previous studies suggest that these events can be reduced by repeat
infusions of levosimendan in patients with advanced heart failure.